Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
A phase 3 trial of XLJDOD compound granule in colorectal cancer, run by Jiangsu Famous Medical Technology Co., Ltd., now recruiting.
Overview
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer is a phase 3 interventional study registered as NCT05709249 by Jiangsu Famous Medical Technology Co., Ltd., with 730 participants planned, started 2022-12-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: XLJDOD compound granule and placebo (XLJDOD mimetic agent).
Similar pages
not linked directly; found by shared links- TrialA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of Gixam's Performance in a FIT Negative Population
Shares Colorectal cancer and the tag pipeline.
- TrialIsunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Shares Colorectal cancer and the tag pipeline.
- TrialTo Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.
Shares Colorectal cancer and the tag pipeline.
- TrialEvaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.
- TrialA Clinical Study of Arfolitixorin in Patients With mCRC
Shares Colorectal cancer and the tag pipeline.
- TrialFirst-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Shares Colorectal cancer and the tag pipeline.